Seifert M. · Kneiseler G. · Dechene A.

Author affiliations

Department of Gastroenterology, Hepatology and Endocrinology, University Hospital, Paracelsus Medical University Nuremberg, Nuremberg, Germany

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: June 07, 2022
Accepted: December 12, 2022
Published online: March 08, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) can lead to many extrapulmonary manifestations. In this case series, we report on 7 patients developing secondary sclerosing cholangitis (SSC) after severe COVID-19 with intensive care treatment. Methods: Between March 2020 and November 2021, 544 patient cases with cholangitis treated at a German tertiary care centre were screened for SSC. Patients found to be suffering from SSC were assigned to COVID-19 group if SSC presented after a severe course of COVID-19 and to non-COVID-19 group if not. Peak liver parameters as well as intensive care treatment factors and data generated from liver elastography were compared between both groups. Results: We identified 7 patients who developed SSC after a severe course of COVID-19. In the same period, 4 patients developed SSC due to other causes. Mean values of gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) were higher in the COVID-19 group than in the non-COVID-19 group (GGT: 2,689 U/L vs. 1,812 U/L and ALP: 1,445 U/L vs. 1,027 U/L), whereas intensive care treatment factors were comparable in both groups. Only the mean duration of mechanical ventilation was shorter in the COVID-19 group than in the non-COVID-19 group (22.1 days vs. 36.7 days). Liver elastography indicated a fast progression to liver cirrhosis with a mean liver stiffness of 17.3 kilopascals (kPa) in less than 12 weeks in the COVID-19 group. Conclusions: Our data suggest a more severe course of SSC when caused by SARS-CoV-2. Reasons for this are probably multifactorial, including a direct cytopathogenic effect of the virus.

© 2023 S. Karger AG, Basel

References WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/ Website accessed on October 10, 2022. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul;26(7):1017–32. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271–80.e8. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020 Jun;10(6):779–82. Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol. 2009 May;6(5):287–95. Brooling J, Leal R. Secondary sclerosing cholangitis: a review of recent literature. Curr Gastroenterol Rep. 2017 Sep;19(9):44. Martins P, Verdelho Machado M. Secondary sclerosing cholangitis in critically ill patients: an underdiagnosed entity. GE Port J Gastroenterol. 2020 Feb;27(2):103–14. Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care. 2015 Mar 31;19(1):131. Schade I, Radakovic D, Hoffmann J, Sommer SP, Stefenelli U, Schimmer C, et al. Secondary sclerosing cholangitis in cardiac surgical patients: a complication with a dismal prognosis. J Thorac Cardiovasc Surg. 2017 Sep;154(3):906–12. Gelbmann CM, Rummele P, Wimmer M, Hofstadter F, Gohlmann B, Endlicher E, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol. 2007 Jun;102(6):1221–9. Ben-Ari Z, Levingston D, Weitzman E, Haviv-Yadid Y, Cohen-Ezra O, Weiss P, et al. Secondary sclerosing cholangitis following major burn. Ann Hepatol. 2015 Sep–Oct;14(5):695–701. Sundaram V, Bjornsson ES. Drug-induced cholestasis. Hepatol Commun. 2017 Oct;1(8):726–35. Knooihuizen SAI, Aday A, Lee WM. Ketamine-induced sclerosing cholangitis (KISC) in a critically ill patient with COVID-19. Hepatology. 2021 Jul;74(1):519–21. Gudnason HO, Bjornsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol. 2017;10:105–11. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020 Aug;54:62–75. Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: prospective therapeutic challenges. World J Gastroenterol. 2021 Apr 21;27(15):1531–52. Durazo FA, Nicholas AA, Mahaffey JJ, Sova S, Evans JJ, Trivella JP, et al. Post-Covid-19 cholangiopathy-A new indication for liver transplantation: a case report. Transpl Proc. 2021 May;53(4):1132–7. Aghayari Sheikh Neshin S, Shahjouei S, Koza E, Friedenberg I, Khodadadi F, Sabra M, et al. Stroke in SARS-CoV-2 infection: a pictorial overview of the pathoetiology. Front Cardiovasc Med. 2021;8:649922. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020 Oct;11(10):771–5. Lui VCH, Hui KPY, Babu RO, Yue H, Chung PHY, Tam PKH, et al. Human liver organoid derived intra-hepatic bile duct cells support SARS-CoV-2 infection and replication. Sci Rep. 2022 Mar 30;12(1):5375. Hunyady P, Streller L, Rüther DF, Groba SR, Bettinger D, Fitting D, et al. Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study. Clin Infect Dis. 2022 Jul;9:ciac565. Online ahead of print. Arnstadt B, Zillinger C, Treitl M, Allescher HD. Corona again? SSC after a severe COVID-disease. Z Gastroenterol. 2021 Dec;59(12):1304–8. Klindt C, Jensen BE, Brandenburger T, Feldt T, Killer A, Schimmoller L, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: a case report and review of the literature. Clin Case Rep. 2021 May;9(5):e04068. Meersseman P, Blondeel J, De Vlieger G, van der Merwe S, Monbaliu D; Collaborators Leuven Liver Transplant program. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med. 2021 Sep;47(9):1037–40. Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, et al. Post-COVID-19 cholangiopathy: a novel entity. Am J Gastroenterol. 2021 May 1;116(5):1077–82. Tafreshi S, Whiteside I, Levine I, D’Agostino C. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging. 2021 Dec;80:239–42. Article / Publication Details

First-Page Preview

Received: June 07, 2022
Accepted: December 12, 2022
Published online: March 08, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.